

Special Issue

Epigenetic Regulation and Antitumor Immune Responses

Message from the Guest Editors

The immune system plays a pivotal role in the recognition and killing of tumor cells. Along with tumor progression, tumor is continuously edited by the immune system, while the immune system is simultaneously shaped by the tumor microenvironment. Tumor immune escape mechanisms emerge, namely, downmodulation of antigen presentation machinery and immune cell differentiation into immunosuppressive and dysfunctional phenotypes. This unremitting bidirectional shaping of the tumor/immune system axis is acknowledged to be significantly modulated by epigenetic mechanisms. Hence, the understanding of epigenetic-mediated processes involved in (i) tumor cell escape from immune killing and (ii) the plastic differentiation of immune cells towards dysfunction or immunosuppression is of utmost importance for the understanding of tumor biology, and for the design of novel therapeutic strategies targeting epigenetic mechanisms. Thus, in this Special Issue, we aim to cover all relevant aspects involved in cancer immunoepigenetics and immune escape, including basic and translational research.

Guest Editors

Prof. Dr. Carmen Jerónimo

Dr. Jesús M. Paramio

Dr. Margareta P. Correia

Deadline for manuscript submissions

closed (31 July 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/92150

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).